Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

NCT03262454 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Small Cell Lung Cancer Recurrent

Interventions

DRUG: Atezolizumab

Sponsor

National Cancer Center, Korea

Collaborators

[object Object]